Important updates

Important updates

 

Lung cancer

Colorectal (bowel) cancer

Breast cancer

Prostate cancer

Childhood cancer

Cervical

Brain & Central Nervous System Cancer

Melanoma and Skin cancer

Plasma Cell Neoplasms (Including Multiple Myeloma)

Pancreatic cancer

Ovarian Cancer

Leukemia

Lung cancer

 

Glycyrrhetinic acid
Glycyrrhetinic acid is a bioactive component of licorice
This study demonstrated, for the first time, that Glycyrrhetinic acid decreased cell proliferation of Non-Small Cell Lung Cancer cells.

Hydrogen Peroxide (H2O2)
This study says that H2O2, is a very interesting potential therapeutic tool to fight cancer. The proper and cautious use of H2O2 in combination with commonly used chemotherapeutic drugs may have synergistic effects increasing lung cancer cell death. Particularly, novel therapeutic approaches combining H2O2 with repositioned drugs may help to decrease the mortality from this malignancy.
See
Hydrogen Peroxide (H2O2)

For many lung cancer patients, Keytruda is a better initial treatment than chemotherapy, study finds

Source: Los Angeles Times
By Melissa Healy Jun 05, 2018

In findings that may allow many lung cancer patients to avoid chemotherapy, a large clinical trial has shown that the immunotherapy drug Keytruda is a more effective initial treatment for two-thirds of patients with the most common type of lung cancer.

Compared with advanced small-cell lung cancer patients who got chemotherapy, those treated first with Keytruda had a median survival time that was four to eight months longer.

The difference was greatest among patients whose cancers harbored high levels of the genetic mutations Keytruda uses to target malignancy. But even patients whose cancers had very low levels of these mutations outlived patients who got chemotherapy by a median of four months.

In addition, treating lung cancer patients with Keytruda improved quality of life. Among those who got the immunotherapy drug, only 18% experienced severe side effects, compared with 41% on chemotherapy.

The findings, presented this week at the annual meeting of the American Society of Clinical Oncology, will probably expand Keytruda’s use as a first-line treatment for advanced small-cell lung cancer, the most common form of the disease.
Read the full article in Los Angeles Times

Overdiagnosis.
Some cancers that are diagnosed early do not develop symptoms requiring treatment, while others grow so slowly that the patient outlives the cancer and dies of other causes. Many of these are treated unnecessarily, leading to inflated survival rates.

The authors of this study which looked at cancer overdiagnosis stated: We estimate the magnitude of overdiagnosis from randomized trials: about 50% of chest x-ray and/or sputum-detected lung cancers.

Colorectal (bowel) cancer

 

Screening for Bowel Cancer

In Ireland – a BowelScreen Test Kit is offered free to men and women aged 60-69 by The National Bowel Screening Programme
This is a test you carry out in your own home.

You can also purchase the kit from PrivaPath Diagnostics

Other countries:
Test kits may be supplied by your Health Service or can be purchased in pharmacies and online.

Chemotherapy worsens outcomes in Stage II colon cancer patients.

This study followed 453 stage II colon cancer patients over a two year period following diagnosis. The study authors concluded:

In this study, stage II colon cancer patients who received chemotherapy treatment were more likely to have poor quality of life, recurrence, and all-cause mortality after 24 months compared to those who did not receive chemotherapy.

Colon Cancer – Risk of Recurrence?

Oncotype DX® Colon Cancer Assay
Article source: Oncotypedx
Test available from: Oncotypedx

The Oncotype DX® Colon Cancer Assay quantifies recurrence risk in stage II and stage III colon cancer, beyond traditional qualitative measures. This enables an individualized approach to treatment planning. The Oncotype DX test measures a group of cancer genes in the tumor, providing a quantitative Recurrence Score® result beyond traditional measures so physicians and patients can have a more complete discussion of recurrence risk.

The Oncotype DX® Recurrence Score® result, when combined with mismatch repair status and T-stage, provides an individualized, quantitative and reproducible assessment of recurrence risk to help guide treatment decision-making for patients with stage II and stage III colon cancer.

Anti-parasite drug, nitazoxanide (NTZ)
Source: Labiotech.eu

A group from the University of Bergen have been testing hundreds of drugs to see how they affect cancer cells. They have now found a drug taken to treat intestinal parasites, Giardia and tapeworms, which acts as a tailored medicine against prostate and colon cancer. A widely used anti-parasite drug, nitazoxanide (NTZ), is able to break down a protein called beta-catenin, which is found at high levels in prostate and colon cancer cells and supports their growth and survival. This opens up the possibility of repurposing the drug for the treatment of these cancers.

Vitamins C and K3
This study
concluded Vitamins C and K3 have significant antiproliferative and apoptotic (cell death) effects when used in combination. This combination enhances the efficacy of gemcitabine against bladder cancer in humans.

Chaga Mushrooms
In some studies, Chaga demonstrates selective apoptosis in tumor cells with no effects on healthy cells. Chaga extract has inhibitory and proapoptotic effects against colon cancer.
See Chaga Mushrooms

Mistletoe (Iscador)
Many studies involve using Mistletoe as adjuvant therapy in patients with cancer. One retrospective cohort study done in Europe between 1993 and 2000 looked at the use of a mistletoe extract (Iscador) as long-term adjuvant therapy in 800 patients treated with chemotherapy and/or radiation therapy for colorectal cancer that had not spread. The study found that patients treated with Iscador had fewer adverse events, better symptom relief, and improved disease-free survival compared to patients who did not receive Iscador as adjuvant therapy.
See Mistletoe

Ipilimumab
According to the National Cancer Institute, Ipilimumab is approved to treat:
Colorectal cancer in adults and children 12 years and older.
It works by helping the body to slow or stop the growth of cancer cells.
See
Ipilimumab

Taurolidine
An anti-biotic that is being studied in the treatment of cancer. It promotes apoptosis by inducing various apoptotic factors and suppresses the production of vascular endothelial growth factor (VEGF), a protein that plays an important role in angiogenesis.

Furthermore, taurolidine seems to reduce established lung metastases in in vivo model. Taurolidine may offer additional therapeutic options in patients with colon adenocarcinoma.
See
Taurolidine

Ukrain
This study, published in the European journal of Cancer states:
In a randomised study 108 patients with advanced colorectal cancer, average 61.2 years, were included. 54 patients were treated with Ukrain as monotherapy and 54 with 5-fluororacil. The therapy results (clinical, haematological, immunological, biochemical) show that Ukrain has favourable properties in the treatment of colorectal cancer and clearly show advantages in contrary to 5-fluorouracil. Stability of the disease was reached in 88.8% and only 27.7% in the control group. The pretreatment with Ukrain facilitated the operability of the patients. The malignotoxic action of Ukrain in the clinic is confirmed by the results of pathomorphosis that gives more possibilities in operative treatment and increases the survival rate. Ukrain is a new effective drug in the therapy of colorectal cancer.

Did you know…
A 2016 study of patients with advanced colon cancer found those with tumors on the right side survived an average of 19 months, compared to 33 months for those with tumors on the left side.

Source: CBS News

 

Breast cancer

 

Surgery in second half of menstrual cycle increases survival.

Research shows that women with breast cancer can sharply improve their chances of survival by timing surgery in the second half of their menstrual cycle.

Women who have breast tumours removed during the first part of the cycle have a survival rate after 10 years of 45 per cent. The survival rate is 75 per cent for women who have the operation in the latter part of the month.


Osteoporosis drug could be used to treat aggressive form of breast cancer, researchers say

This study says an enzyme called UGT8 drives the progression of basal-like breast cancer, an aggressive form of the disease that is largely untreatable. It found that the widely used osteoporosis drug zoledronic acid inhibits UGT8 and prevents the spread of basal-like breast cancer in mice, suggesting that this drug could also be used to treat the disease in humans.


Carotenoids and Selenium prevent Recurrence

This study found that Carotenoids and Selenium can prevent breast cancer returning. Cruciferous vegetables contain Carotenoids and Selenium is available as a supplement.


DHA oil inhibits breast cancer cell growth
This study
demonstrated that Docosahexaenoic acid (DHA) oil inhibited the growth and induced the death of Breast Cancer cells.

DHA is an omega-3 fatty acid found in cold-water oily fish and in seaweed. DHA is also widely available in supplement form.


Blueberries
This study
says eating blueberries can inhibit breast cancer tumor growth.


Aggressive treatment of D.C.I.S. with radiotherapy or mastectomy does not prevent death from breast cancer.

This long-term study was published in the journal JAMA Oncology in 2015. The analysis of 20 years of patient data made the case for a less aggressive approach to treating a condition known as ductal carcinoma in situ, or D.C.I.S., for which the current practice is nearly always surgery, and often radiation. The results suggest that the form of treatment may make no difference in outcomes.


Overdiagnosis of breast cancer.

Definition of Overdiagnosis (National Cancer Institute)
Finding cases of cancer with a screening test (such as a mammogram or PSA test) that will never cause any symptoms. These cancers may just stop growing or go away on their own. Some of the harms caused by overdiagnosis are anxiety and having treatments that are not needed.

Some cancers that are diagnosed early do not develop symptoms requiring treatment, while others grow so slowly that the patient outlives the cancer and dies of other causes. Many of these are treated unnecessarily, leading to:

  • Unnecessary tests and treatment
  • Exposure to dangerous side-effects
  • Radiation-induced cancers
  • Mental and physical pain
  • Infertility
  • Inflated survival rates

The authors of this study which looked at cancer overdiagnosis stated: We estimate the magnitude of overdiagnosis from randomized trials: about 25% of mammographically detected breast cancers

This Article, published in 2012 in the New England Journal of Medicine, found: 31% of all breast cancers are over-diagnosed.

This 2016 review concluded:
· At least 20% of Breast Cancer patients, if left untreated would be alive after 5 years
· limited evidence suggests that around 10% of screen detected Breast Cancers may regress.


TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy

June 3, 2018
Source: National Cancer Institute

New findings from the groundbreaking Trial Assigning Individualized Options for Treatment (Rx), or TAILORx trial, show no benefit from chemotherapy for 70 percent of women with the most common type of breast cancer. The study found that for women with hormone receptor (HR)positive, HER2-negative, axillary lymph node­–negative breast cancer, treatment with chemotherapy and hormone therapy after surgery is not more beneficial than treatment with hormone therapy alone. The new data, released at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, will help inform treatment decisions for many women with early-stage breast cancer.

The trial was supported by the National Cancer Institute (NCI), part of the National Institutes of Health, and designed and led by the ECOG-ACRIN Cancer Research Group. Findings from the study will be published in The New England Journal of Medicine.

“The new results from TAILORx give clinicians high-quality data to inform personalized treatment recommendations for women,” said lead author Joseph A. Sparano, M.D., associate director for clinical research at the Albert Einstein Cancer Center and Montefiore Health System in New York City and vice chair of the ECOG-ACRIN Cancer Research Group. “These data confirm that using a 21-gene expression test to assess the risk of cancer recurrence can spare women unnecessary treatment if the test indicates that chemotherapy is not likely to provide benefit.”

TAILORx, a phase 3 clinical trial, opened in 2006 and was designed to provide an evidence-based answer to the question of whether hormone therapy alone is not inferior to hormone therapy plus chemotherapy. The trial used a molecular test (Oncotype DX Breast Recurrence Score) that assesses the expression of 21 genes associated with breast cancer recurrence to assign women with early-stage, HR-positive, HER2-negative, axillary lymph node­–negative breast cancer to the most appropriate and effective post-operative treatment. The trial enrolled 10,273 women with this type of breast cancer at 1,182 sites in the United States, Australia, Canada, Ireland, New Zealand, and Peru.

When patients enrolled in the trial, their tumors were analyzed using the 21-gene expression test and assigned a risk score (on a scale of 0­–100) for cancer recurrence. Based on evidence from earlier trials, women in the trial who had a score in the low-risk range (0­–10) received hormone therapy only, and those who had a score in the high-risk range (26 and above) were treated with hormone therapy and chemotherapy.

Women in the trial who had a score in the intermediate range (11­–25) were randomly assigned to receive hormone therapy alone or hormone therapy with adjuvant chemotherapy. The goal was to assess whether women who received hormone therapy alone had outcomes that were as good as those among women who received chemotherapy in addition to hormone therapy.

“Until now, we’ve been able to recommend treatment for women with these cancers at high and low risk of recurrence, but women at intermediate risk have been uncertain about the appropriate strategy to take,” said Jeffrey Abrams, M.D., associate director of NCI’s Cancer Therapy Evaluation Program. “These findings, showing no benefit from receiving chemotherapy plus hormone therapy for most patients in this intermediate-risk group, will go a long way to support oncologists and patients in decisions about the best course of treatment.”

The researchers found that the primary endpoint of the trial, invasive disease-free survival—the proportion of women who had not died or developed a recurrence or a second primary cancer—was very similar in both groups. Five years after treatment, the rate of invasive disease-free survival was 92.8 percent for those who had hormone therapy alone and 93.1 percent for those who also had chemotherapy. At nine years, the rate was 83.3 percent for those with hormone therapy alone and 84.3 percent for the group that had both therapies. None of these differences were considered statistically significant.

The rates of overall survival were also very similar in the two groups. At five years, the overall survival rate was 98.0 percent for those who received hormone therapy alone and 98.1 percent for those who received both therapies, and at nine years the respective overall survival rates were 93.9 percent and 93.8 percent.

The researchers also found that women with a score of 0–10 had very low recurrence rates with hormone therapy alone at nine years (3 percent). This confirms similar findings from earlier studies. In addition, they found that women with a score of 26–100 had a distant recurrence rate of 13 percent despite receiving both chemotherapy and hormone therapy. This finding indicates the need to develop more effective therapies for women at high risk of recurrence.

According to the authors, the new findings suggest that chemotherapy may be avoided in about 70 percent of women with HR-positive, HER2-negative, node-negative breast cancer:

  • older than 50 and with a recurrence score of 11–25 (45 percent)
  • any age with a recurrence score of 0–10 (16 percent)
  • 50 years old or younger with a recurrence score of 11–15 (8 percent)

The findings suggest that chemotherapy may be considered for the remaining 30 percent of women with HR-positive, HER2-negative, node-negative breast cancer:

  • any age with a recurrence score of 26–100 (17 percent)
  • 50 years old or younger with a recurrence score of 16–25 (14 percent)

The new results demonstrate that chemotherapy is not beneficial for most women in the intermediate-risk group. This data adds to findings from a TAILORx analysis published in 2015 that provided prospective evidence that the gene expression test could identify women with a low risk of recurrence who could be spared chemotherapy.

There is one caveat to the new findings. When the researchers analyzed premenopausal women and those younger than 50 years old at the higher end of the intermediate-risk range (16–25) separately, the results showed there may be a small benefit from chemotherapy, and thus these women should consider chemotherapy with their doctor. However, it is unclear if this benefit is due to the effect of chemotherapy or to endocrine suppression caused by chemotherapy-induced menopause.

“Before TAILORx, there was uncertainty about the best treatment for women with a mid-range score of 11–25 on the Oncotype DX Breast Recurrence Score test. The trial was designed to address this question and provides a very definitive answer,” said Dr. Sparano. “Any woman with early-stage breast cancer age 75 or younger should have the 21-gene expression test and discuss the results with her doctor to guide her decision to the right therapy.”

TAILORx was one of the first large-scale trials to examine a methodology for personalizing cancer treatment. When the trial was activated, the best available genomic profiling data in women with early-stage breast cancer were retrospective.

The study was supported in part by the Breast Cancer Research Foundation, Komen Foundation, and the Breast Cancer Research Stamp. The stamp funding provided more than $5 million to the trial. Since 1998, when the charity stamp was authorized by Congress and first issued by the United States Postal Service, more than $86 million has been raised for breast cancer research. The net proceeds from sales of the stamp are transferred to NIH and the Medical Research Program of the Department of Defense to fund breast cancer research.

The genomic assay used in the trial was the Oncotype DX Breast Recurrence Score test from Genomic Health, Inc., Redwood City, California.

Here are a few quick facts about the trial:

It was the largest randomised adjuvant breast cancer treatment trial ever conducted.
It
found most women with early breast cancer do not benefit from chemotherapy

Study details:
10,273 Patients
1,182 Trial Sites
6 participating countries: United States, Australia, Canada, Ireland, New Zealand, and Peru.
9 year outcomes
Sponsored by the US National Cancer Institute
Study Results published in The New England Journal of Medicine

The purpose of the trial was to find out whether women treated with Hormone therapy alone would fare as well over time as those treated with Hormone therapy plus Chemotherapy.

The findings: At 9 years, the two treatment groups had similar rates of invasive disease–free survival (83.3% in the hormone-therapy group and 84.3% in the Hormone plus Chemotherapy group),
freedom from disease recurrence at a distant site (94.5% and 95.0%)
or at a distant or local–regional site (92.2% and 92.9%),
and overall survival (93.9% and 93.8%).

You can see the study at The New England Journal of Medicine

 

Prostate cancer

 

Hormone therapy can make prostate cancer worse, study find.

Source: Science Daily / University of Toronto
Scientists have discovered how prostate cancer can sometimes withstand and outwit a standard hormone therapy, causing the cancer to spread. Their findings also point to a simple blood test that may help doctors predict when this type of hormone therapy resistance will occurcontinue reading
( link to original study)


Medical treatment a waste of time in men over 55 diagnosed with prostate cancer

WARNING: PROSTATE CANCER DIAGNOSED?

MEN – Do not do a thing until you read this!

A growing number of research studies shows that there is little or no survival benefit in having orthodox medical prostate cancer treatment if you are diagnosed over the age of 50. With the known and common side-effects, you are probably better off doing absolutely nothing or looking at non-invasive alternative treatments, and later in the article, we will cover some of those.

Other studies have exposed more medical mythology. Experts now view the PSA test as virtually useless, while others are clear that testosterone levels have no causal effect on prostate cancer.

And, let’s be clear, after the age of 50-55, at least 4 out of every 10 men will develop prostate cancer!

“No survival advantage in prostate cancer treatment”

In August 2016, a major research study by Professor Freddy Hamdy and his Oxford University team found that there is absolutely no survival advantage in having orthodox medical treatment for a newly diagnosed prostate cancer patient after 50 years of age.

The 2016 NHS study followed more than 82,000 men aged between 50 and 69 for a decade. And the bottom line? Only 1 per cent of the men died in that time from their cancer, whether or not they had treatment! The fact is that in the great majority of men diagnosed with prostate cancer later in life, the cancer is slow growing. You are more likely to die with it, than of it.

Importantly, this study was not the first of its kind, as you will see below, but it was the biggest, and in all such studies the results have been remarkably consistent bringing in to question the worth of orthodox medical treatment for prostate cancer in men over 55 years of age, especially in the light of its known high levels of side-effects.

PSA tests, false positives and completely unnecessary prostate cancer treatment

In 2012 there was a full report from the American Preventive Services Task Force (PSTF) on prostate cancer. This Government body concluded that PSA tests for prostate cancer were unreliable, do not offer men any tangible benefit in lifespan or quality of life, and conclude that many more men are injured than helped by PSA tests.

The PSTF research concluded that “only one man in a thousand tested would derive any real benefit, whereas a staggering 100 will receive false positives. Many of these people will then have biopsies, which can cause complications including infection”.

Prostate Specific Antigen (PSA) is a biological marker that oncologists and doctors use to detect the presence of a potential prostate tumour. However there are many other reasons why the PSA can be high; for example, you cycled in the previous 24 hours, consumed dairy, you have prostatitis (inflammation or infection in the prostate gland), or benign prostatic hyperplasia (BPH), or you went to the gym on the way to the hospital. Equally consuming lycopene (tomatoes) or eating a cooked tomato-rich meal will temporarily lower the score.

Also many prostate tumours are benign, would never cause serious health problems yet give high PSA readings.

The same study found that 90 per cent of men may then be treated with surgery or radiation for cancers that are not and will never be life-threatening, but five out of every thousand having these treatments will die within a month of initiating them. In other words, more than ten percent of all men screened for prostate cancer will generate false positives that could result in death from treatment, while a mere 0.001 percent or less will derive any sort of benefit.

“There is a small potential benefit and a significant known harm,” said Dr. Virginia A. Moyer, a professor of paediatrics at Baylor College of Medicine in Houston, Texas, and chair of the task force. She and her team are recommending that the PSA test for prostate cancer be abandoned altogether, and that patients avoid the test as part of their normal check-ups.

No link between testosterone levels and prostate cancer

Many doctors state that PSA tests might be imperfect but they are all that is available, so they might as well use them. This is actually not true. In America some experts measure the DHT levels.

DiHydroTestosterone (DHT) is the active compound, produced by the action of oestrogen on nice safe testosterone. DHT is what causes prostate cancer and the test is also a measure of cancer aggression.

Be clear: There is absolutely no link between prostate cancer and testosterone levels according to Peter Boyle, MD, of the International Prevention Research Institute, who reviewed two meta-studies and found no evidence that testosterone levels were linked in either.

No real benefit in prostate cancer surgery and hormone treatment but there are many problems

In research published in theJournal of the National Cancer Institute, Swedish researchers have concluded that if none of the men diagnosed with early prostate cancer had any treatment at all, over 97 per cent would still survive ten years or more!

After comparing a group of low to mid-risk prostate patients having no treatment with a group having the usual surgery and hormone treatments, some eight years later the death rate amongst men in the no-treatment (active surveillance) group was exactly the same as the figure for the general population!! The researchers stated that after ten years only a little over two per cent of men in the untreated group would have died from prostate cancer.

The researchers even suggested having surgery was pretty much a waste of time and made no difference to the outcome; worse, patients had to put up with often debilitating side-effects.

In a second study (New England Journal of Medicine – PIVOT study) led by Dr.Timothy Wilt of the University of Minnesota School of Medicine, 731 men were followed for ten years, after being diagnosed with prostate cancer. Some had surgery, some did nothing.

At the end of the ten years 47 per cent of the surgery men died during the study compared with 50 per cent of those having nothing. This difference is not deemed statistically significant. However, importantly, men who choose to do nothing are only half as likely to suffer from urinary incontinence or erectile dysfunction.

“We think our results apply to the vast majority of men diagnosed with prostate cancer today,” said Dr. Wilt to the Chicago Tribune.

Importantly, in this study only 3 per cent of men diagnosed with prostate cancer actually died from it, whether they had had surgery or not! The rest died of other causes!

So this study also shows orthodox prostate treatment in men over 60 does not extend life. However, men who have surgery are much more likely to suffer side-effects – overall more than 50 per cent suffer impotence, and more than 10 per cent suffer incontinence.

Over 55 and diagnosed with prostate cancer? Watch and wait

Both the US National Health Institutes and the American Society of Clinical Oncology recommend ‘Active surveillance’, or ‘Active Monitoring’. The ‘cut off’ is a Gleeson score of 6 or lower. Starting once every three months then every 6 months this may become once per year and then once every two years. 50 per cent of men diagnosed in America in 2016 with early stage prostate cancer now ‘watch and wait’. CANCERactive first recommended this strategy in 2005, 11 years ago and four years ahead of other UK charities. Five years ago in America only 10 per cent of men followed Active surveillance programmes.

One expert US oncologist Dr. Matthew R. Cooperberg, a urologist and epidemiologist at the University of California, San Francisco, is actually arguing for new terminology that says there is abnormality but doesn’t use the ‘C’ word. Cooperberg observes that life expectancy in the over 60s is 10-15 years when diagnosed, even without treatment.

IMPORTANT: Can you take your own steps to treat your prostate cancer and live longer?

The idea of simply ‘waiting’ can fill men with some horror. But then so too can the thought of prostate surgery, drugs to cut testosterone, radiotherapy and debilitating side-effects.

So can you take matters in hand? The answer is an emphatic ‘Yes’.

1. Prostate cancer risk and aggression increases the more saturated fat, such as cows’ dairy, and alcohol you consume. Higher triglyceride levels in the blood stream are known to progress the disease.
2. Conversely, diets high in polyphenols (such as pomegranate, curcumin, resveratrol and EGCG in green tea) slow growth. One supplement, POMI-T, developed by Professor Robert Thomas has been shown to reduce PSA levels in clinical trials. Thomas originally had all newly diagnosed men around his hospital on broccoli, tomatoes and light daily exercise, pushing back the need for surgery by at least three years. Oestrogen regulators like Indole 3 Carbinol and melatonin also help slow the process.
3. A good diet and lifestyle can limit prostate cancer growth rate. And there is research concluding that both curcumin and grape seed extract can reduce metastases in prostate cancer.
4. German Clinics (such as Klinik St Georg) have evidence that prostate biopsies, apart from risking infection and impotence, can spread the disease. There are UK clinical studies concluding the same. Do you really need a biopsy?
5. Rather than invasive surgery, men should look into localised hyperthermia (also called Ablation). This can melt away the tumour and hospitalisation is short with side-effects minimal. The prostate tumour can be heated using High Intensity Focused Ultrasound (HIFU) or a tube with a metal element placed in the middle of the tumour.
6. The Nanoknife IRE, which uses needles either side of the tumour and passes a current through the tumour to punch holes in the cancer cells causing them to lyse, is another potential option.
7. Instead of radiotherapy and brachytherapy, less damaging and more contained proton therapy is now increasing in popularity in America.
8. Research in 2008 linked 13 chemicals to prostate cancer. All these chemicals were ‘oestrogen mimics’. Research has shown that where selenium levels are low, supplementation of up to 200 micrograms can have positive effects. Selenium can displace chemicals and heavy metals from the body.
9. Vitamin D, the sunshine vitamin, has been shown in research to reduce both risk and aggression. Public Health, England advise everybody to go in the sun and, if you can’t, to supplement. Harvard Medical School advise supplementation at 5,000IUs per day for people with cancer.
10. Men who incorporate a higher overall ratio of plant-based foods and herbs into their diets reduce aggressive prostate cancer risk by 25 per cent according to a University of South Carolina study. Researchers claimed the benefit came from bioactive compounds called flavonoids found in colourful foods (for example, strawberries, grapes, greens, onions, citrus fruits).
11. Another study showed the higher your consumption of naturally fibrous foods the stronger your immune system; while yet another showed the same high-fibre diet slowed prostate cancer growth.
12. Maintaining a healthy gut (taking probiotics and probiotic foods like Kefir, Sauerkraut and unpasteurized milk products) can boost the immune system and lower bad triglyceride levels. Extra virgin olive oil, fish oils and consuming nuts and seeds can also help significantly.

Did you know?
In 2005, Dr. Dean Ornish MD conducted an interventional study with 93 patients PROVING that you can reverse the progression of early stage prostate cancer with a plant-based diet, exercise, and stress reduction.


Artemisinin (Anti-Malaria drug) and Prostate cancer
This study says: Taken together, our results suggest that artemisinin is a very potent anti-cancer compound that exhibits unique effects on the cell cycle regulation of human prostate cancer cells. As such, artemisinin has the potential to be developed as a potent anti-prostate cancer therapeutic.


Phellinus linteus
Phellinus linteus is a well-known Oriental medicinal fungus with a variety of biological activities, including immunomodulatory or direct antitumor activities, according to this study. Its extracts demonstrated tumor regression in three independent case reports…

We encountered a case of advanced prostate cancer that became resistant to all kinds of hormonal and radiation therapy, but improved dramatically with oral intake of an extract from the mushroom, Phellinus linteus, say the authors of this study.


Anti-parasite drug, nitazoxanide (NTZ)
Source: Labiotech.eu

A group from the University of Bergen have been testing hundreds of drugs to see how they affect cancer cells. They have now found a drug taken to treat intestinal parasites, Giardia and tapeworms, which acts as a tailored medicine against prostate and colon cancer. A widely used anti-parasite drug, nitazoxanide (NTZ), is able to break down a protein called beta-catenin, which is found at high levels in prostate and colon cancer cells and supports their growth and survival. This opens up the possibility of repurposing the drug for the treatment of these cancers.

Pfeifer Protocol for Prostate Cancer

Source: Pfeifer Protocol

Prostate Cancer Protocol Success

Clinical studies are showing this protocol successful in 65% of the patients that Dr. Pfeifer has used it on, even though it has largely been used with patients that have either failed conventional treatments or have been unable to tolerate them. This phytotherapy treatment program has none of the harsh side effects experienced using standard therapies for this disease. The successful results of his trial have been published in the January 2005 edition of Oncology, a Swiss medical journal (www.tellmed.ch). He now lectures around the world educating cancer specialists about his protocol.

This protocol has been reported to produce 50% reduction of PSA by 6 months in up to 70% of such patients treated in Switzerland with minimal side effects (Pfeifer and Aeikens Positive Health 2006, 120:19-25/ www.positivehealth.com).

Continue reading about this treatment at Pfeifer Protocol

See also
Complementary Therapies for Hormone Refractory Prostate Cancer


Prostate Cancer – Risk of Recurrence?

Oncotype DX® Prostate Cancer Assay
Article source: Oncotypedx
Test available from: Oncotypedx

The Oncotype DX Prostate Cancer Assay harnesses the power of genomics to provide a more precise and accurate assessment of risk based on individual tumor biology. Using a minimal tissue sample from a needle biopsy, the test builds on traditional clinical pathologic factors to provide additional, clinically relevant insight into the underlying prostate tumor biology, enabling physicians and their patients to make treatment decisions with greater confidence.

Patients with newly diagnosed low-risk prostate cancer—and their urologists—need to know the aggressiveness of their tumor. The Oncotype DX Prostate Cancer Assay can help. This genomic test performed on a patient’s needle biopsy provides essential insight into the underlying biology of that patient’s prostate cancer. The result is reported as the Genomic Prostate Score or GPS, and provides a more precise, accurate, and individualized risk assessment that can help a patient and his urologist make a confident choice between active surveillance and immediate treatment.

Childhood cancer

Survivors of Childhood Cancer – Long term effects.

This study published in The Lancet in 2017 estimated that, on average, a survivor of childhood cancer will experience 11 non-fatal chronic health conditions including an average of 3 severe or life-threatening conditions.

This 2017 study shows that a review into more than 1,200 published articles found that

  • The average life expectancy of childhood cancer survivors is 30 per cent lower than the general population.
  • Childhood cancer survivors are up to six times more likely to develop a secondary cancer, compared with the general population.

In general, cancer survivors are also more likely to develop long term conditions, such as heart problems, lung scarring, secondary cancers and frailty. They will also get age-associated illnesses sooner than the general population, the analysis suggests.

The researchers say much of the illness and accelerated ageing is down to harsh treatments such as chemotherapy and radiotherapy, which damage the body’s ability to fight back from illness and repair itself.

Some cancer drugs were also found to be associated with hearing loss, reduced thyroid gland activity, high blood pressure, congestive heart failure, muscular weakness, arthritis, kidney and liver diseases, chronic constipation, and infertility.

While ageing prematurely is a better alternative to dying prematurely, the use of effective non-toxic treatments would, obviously, be a far better approach.

Much more detailed information here


Cannabis prevents nausea and vomiting in children undergoing cancer treatment.

A study An efficient new cannabinoid antiemetic in pediatric oncology (Life Sciences, May 1995 ) found:
…the prevention of vomiting was complete, regardless of the antineoplastic protocol followed . We observed no delayed nausea or vomiting. Although the number of pediatric cancer patients treated so far is small, the total number of treatments is considerable (480 times) as most patients underwent several treatment cycles. Without the cannabinoid therapy we would have expected the patients to vomit in most treatments.

In summary, the complete success in preventing vomiting due to antineoplastic treatment in children, and the essential lack of side effects, leads us to believe that delta-8-THC at a dose considerably higher than the doses of delta-9-THC usually administered to adults, can serve as a new, inexpensive antiemetic agent in pediatric cancer chemotherapy.

You can read the full text here

This safe, effective method of preventing nausea and vomiting in children has been known for twenty three years, yet oncologists still prescribe dangerous pharmaceutical drugs instead of delta-9-THC.
Why?


Ultra-clean homes could trigger childhood leukaemia, major review suggests

Keeping children cocooned in ultra-clean homes away from other youngsters could trigger childhood leukaemia, a landmark study suggests.

A major new analysis by Britain’s leading leukaemia expert has concluded a deadly chain of events is set in motion when susceptible children are not exposed to enough bugs to prime their immune system at an early age.

Without sufficient immunity, if vulnerable youngsters catch even a relatively harmless virus like flu, the immune system malfunctions creating far more infection-fighting white blood cells than needed, causing leukaemia.

Read full article in The Telegraph


Childhood Cancer: More Evidence Points to Chemical Exposure

Source: Environmental working Group

Numerous studies have shown links between childhood cancers and exposure to chemicals such as pesticides, benzene and arsenic. EWG has found that not only are these substances widespread in a child’s living environment, they can also be passed on from mother to child during pregnancy and through breastfeeding. (Despite this, the health benefits of breastfeeding greatly exceed the risk of chemical exposure.) These prenatal and early life exposures occur during the most vulnerable period of a child’s development….

… there are steps that parents and all of us can take to reduce exposure to pesticides around the home and harmful chemicals in our personal care products and the household items we use.

Read the full article at Environmental working Group

Childhood acute lymphoblastic leukemia (ALL)

In children with ALL with liver toxicity, Milk Thistle was associated with a trend towards significant reductions in liver toxicity. Milk Thistle does not antagonize the effects of chemotherapy agents used for the treatment of ALL, according to this study

Cervical cancer

Hyperthermia/Ultrasound:

Source: Canceractive.com
In Germany a revolution is taking place. Peter Wurst (Charite Universitatsmedizin, Berlin) has been pioneering the use of hyperthermia and ultrasound. Stage III clinical trials have still to take place but results so far are exceptional. (Int. J. Radiat.Onc.Biol Phys 2006; 66: 1159-67).

All the women in the trials to date had late stage cervical cancer but the tumours could not be removed. Hyperthermia and ultrasound (taking temperatures to 41 degrees in the tumour for 60 minutes, then allowed surgery on 14 patients. Subsequently 3 year survival was 93 per cent. Even the group who did not want surgery thereafter had a 79 per cent 3 year survival.

Immunotherapy and cervical cancer
If a reason for cervical cancer appearing in some women but not in others is down to a poor immune system, it makes sense to be exploring immunotherapy. Sure enough, Keytruda (Pembrolizumab) has been through clinical trials with cervical cancer and is now being used where the cancer has returned after chemotherapy. You can find a review here.

Hesperidin
Hesperidin is a plant chemical that is found primarily in citrus fruits such as oranges, grapefruits, and lemons.

This study says Hesperidin has been proven to be an effective medicine possessing many pharmacological activities such as antioxidant, anti-inflammatory…and inhibition of tumor promoters. Hesperidin has the potential to be developed as a chemotherapeutic or adjuvant agent for human cervical cancer.

AHCC and Cervical Cancer

This study concluded: These data suggest daily dosing of AHCC will eradicate HPV 16/18 infections and may have a role in the prevention of HPV-related cervical cancer. Furthermore, there is a potential for the addition of AHCC to primary treatment regimens for cervical cancer, which may potentially improve response rates and prevent recurrence.

Brain & Central Nervous System Cancer

 

Chinese Skullcap (Scutellaria baicalensis)
This study showed results that support the efficacy of Chinese Skullcap as an anticancer agent for glioblastomas multiforme.

Vitamin C and Doxycycline
This study found that antibiotics, such as Doxycycline, could eradicate Cancer Stem Cells in multiple cancer types. These include: DCIS, breast (ER(+) and ER(-)), ovarian, prostate, lung, and pancreatic carcinomas, as well as melanoma and glioblastoma. The study authors propose the combined use of Doxycycline and Vitamin C as a new strategy for eradicating CSCs.

Falcarinol and falcarindiol
Polyacetylenes derived from carrot and parsley

The authors of this study say they provide several pieces of evidence suggesting that falcarindiol has the anticancer role by targeting glioblastoma cells, as well as glioblastoma stem-like cells.

Metformin (see comp therapies)

For Glioblastoma patients, this study found that a combination of high-dose Metformin and Temozolomide showed the highest cancer cell death activity.


This film charts the remarkable story of Ben Williams, professor emeritus of experimental psychology at University of California, San Diego. Diagnosed in 1995 with the most lethal cancer known to medicine, a primary brain tumour called glioblastoma multiforme, he was given just a few months to live. But a natural born maverick, and rigorous scientist, Ben decided he woud not go down without a fight. Nineteen years later his story is an inspiration to patients the world over, whilst his case is dismissed by the medical community as just one of a handful of statistical outliers...more at SurvivingTerminalCancer.com


Bens Story

Source: CancerActive.com

The Professor who cured his own ´terminal´ brain cancer with a cocktail of non-cancer drugs and supplements

Professor Ben Williams beat GBM, brain cancer using orthodox therapies supported by his own concoction of compounds he added based on his own extensive research.

20 years after his diagnosis, and having celebrated his 70th birthday, he tells how he used cheap, common medicines to build his complementary and integrative programme. And he defied all the odds.

31st March 1995 and Ben Williams, a psychology professor from University of California, San Diego, is undergoing emergency surgery, diagnosed with a terminal glioblastoma, a grade 4 brain tumour. The entire right side of his brain was ‘infested’ with cancer, according to his narrative.

He was told he’d be dead inside a year.

But in 2015 he visited London, and has been clear of cancer since 1998.

At the time of his diagnosis, Ben was 50.

Even today with new treatments, the average survival time is just 15 months. Only 8 per cent of older people last 5 years.

Ben had the surgery. There was still 2 cms of tumour invasion. He considered many options spending hours in the University library, on the Internet and talking with medical friends.

He opted to have BCNU – carmustine – but alternated it with PCV, a three drug combination that has been shown to have positive effects in 75% of people, and negative side-effects in 91%.

But his research had shown him other options. He was interested by how, given one attacking drug, the cancer would mutate and become resistant, so he decided to use several simultaneously. But not the drugs you might expect!

Ben built his own Complementary and Integrative treatment package. He added Tamoxifen (the anti-oestrogenic breast cancer drug – many brain tumours are held in the stem cell state by oestrogen) and verapramil, a calcium channel blocker used for blood pressure treatment, which research showed would enhance chemotherapy action. He also added accutane, a retinoid – of vitamin A origin – used to treat acne but with anti-cancer properties – and melatonin – the insomnia drug, but known to have antioxidant, anti-growth hormone and anti-oestrogenic properties. Finally he used cimetidine (tagamet) which is an antacid. An antihistamine, it is known to stop cancer cells sticking together and forming new tumours.

Throughout his treatment he added supplements like the anti-oestrogenic genestein, PSK (a mushroom extract with strong anti-cancer benefits), flax seed oil (for the fatty acids, helpful to brain tissue, borage seed oil (for gamma-linoleic acid) selenium, milk thistle and green tea extract. He also consumed large quantities of broccoli sprouts, garlic, raspberries and blueberries, onions and soy products. He has been clear according to MRI scans for 20 years now.


Antineoplastons treatment

Antineoplastons were discovered by Stanislaw R. Burzynski, M.D., Ph.D. in 1967 who first identified their anti-cancer properties. Antineoplastons are naturally occurring peptides demonstrating ability to re-program cancer cells without destroying normal cells. Due to their low-toxicity and anti-cancer activity antineoplastons represent a revolutionary avenue in cancer research.
Antineoplastons page

Tumor-treating Fields therapy

TTF therapy is a locally or regionally delivered treatment that uses electric fields within the human body that disrupt the rapid cell division exhibited by cancer cells. TTF therapy was developed to provide physicians and patients with a fourth treatment option for cancer in addition to surgery, radiation therapy and chemotherapy.

Tumor-treating Fields page

Clomipramine

Clomipramine is a drug used for depression, called a tricyclic anti depressant. Some researchers think it might help to treat glioma brain tumours. There has been some lab based research that showed the drug could encourage death of cancer cells, but not healthy brain cells.

Clomipramine page

Boswellia serrata

The resin from Boswellia serrata has an important role in treating brain cancer. Boswellic acid has been shown to demonstrate anti-carcinogenic and anti-tumor activity in several animal models. It also reduces inflammation and prevents metastasis. Boswellia may be doubly useful for primary brain tumors. Studies tell us that in addition to helping reduce cerebral swelling around the tumor, boswellia also kills glioblastoma cells.

Boswellia serrata page

 


Hannah Bradley was successfully treated for Brain tumor by Dr Burzynski

Melanoma and Skin cancer

 

Mole Screening Clinics
If you’re concerned that a mole or skin lesion could be cancerous, you can have it checked out by a dermatologist or other professional trained in early skin cancer detection.

This could save you unnecessary surgery and is painless, fast and very reasonably priced.

In Ireland you can get checked at the following clinics (there are others):

Skincheck Ireland
Tel: 01- 2939148
http://skincheck.ie/

MoleScan Clinic
Tel: 01 685 6569
http://molescan.ie

Outside Ireland:
Check for similar services in your own area.


Other Treatments

Blueberries
This study says Blueberries inhibit the proliferation of melanoma cells.

Vitamin C and Doxycycline
This study found that antibiotics, such as Doxycycline, could eradicate Cancer Stem Cells in multiple cancer types. These include: DCIS, breast (ER(+) and ER(-)), ovarian, prostate, lung, and pancreatic carcinomas, as well as melanoma and glioblastoma. The study authors propose the combined use of Doxycycline and Vitamin C as a new strategy for eradicating CSCs.

Vitamin D
This study says Vitamin D and its analogs have inhibitory effects on cancer stem cell signaling in various types of human cancer cells and may be promising therapeutic/preventive agents against Cancer Stem Cells.

This study says: Several lines of evidence have demonstrated that vitamin D plays an important role in the regulation of stem cells of the prostate and the skin.
Sunlight spurs the body to make vitamin D.
Food sources:
Fish such as salmon, tuna, and mackerel. Small amounts of vitamin D are found in beef liver, cheese, and egg yolks.

BEC 5 for Skin Cancer

The cancer-fighting health benefits of eggplant extract is a phytochemical called solasodine glycoside, or BEC5 and it is especially potent against skin cancer. Curaderm (BEC5 cream) was developed and tested by Dr. Cham and it can be found online without a prescription.


Treating Basal Cell Carcinoma with Aldara

Aldara
Generic name(s) IMIQUIMOD

Uses
This medication is used to treat certain types of growths on the skin. These are precancerous growths (actinic keratoses), a certain type of skin cancer (superficial basal cell carcinoma), and warts on the outside of the genitals/anus. Treating these conditions can decrease complications from them. Imiquimod belongs to a group of drugs called immune response modifiers. It is believed to work by helping to activate your immune system to fight these abnormal skin growths.

Warning:

Aldara: The Skin Cancer “Cure” That Can Kill
by Elaine Hollingsworth

It takes a courageous person, or publication, to reveal the skullduggery of Big Pharma. Occasionally, however, the truth cannot be suppressed, and when The Wall Street Journal revealed that Merck, the maker of Vioxx, had been burying the serious health risks of their COX-2 inhibitor anti-inflammatory drug as far back as March, 2000, a scandal erupted. As Dr. Richard Horton, editor of The Lancet, wrote, “The licensing of Vioxx and its continued use in the face of unambiguous evidence of harm have been public health catastrophes.”

A health catastrophe even more devastating than Vioxx is Aldara or, more specifically, the chemical imiquimod (IQ). IQ is the only active agent in the popular drug known as Aldara, which is marketed worldwide and promoted very heavily by 3M Pharmaceuticals as a “benign” salve to cure skin cancers. IQ has been known since 1986 to cause cancer. It is so dangerous that the American Cancer Society, The National Cancer Institute, and others have determined it is a carcinogen, and have placed it on their lists of most hazardous chemicals. IQ has even been listed as a laboratory chemical hazard by the US Occupational Safety Health Agency. Yet, doctors worldwide are prescribing it in Aldara, willy-nilly, to “cure” skin cancers, even though there are safe, vegetable-based creams and other proven remedies, including surgery. I foolishly used Aldara, and it didn’t kill my skin cancer, but it nearly killed me, leaving me with a damaged immune system. Read full article at: Townsend Letter

Prescription skin cancer cream Aldara has horrific side effects, say users
by: Dani Veracity

Elaine Hollingsworth put Aldara on her nose thinking that it was the “benign salve” that her dermatologist made it out to be; instead, it was the beginning of her nightmare. After using the pharmaceutical skin cancer treatment for only two weeks, a “disgusting, thick, crusty, black scab” covered her entire nose, not just the one-quarter-inch on which she applied the cream — and this wasn’t even the worst side effect.

Around the same time her nose became covered with the scab, Hollingsworth awoke early one morning with a case of anaphylactic shock.

Continue reading at Natural News


Itraconazole

Itraconazole, may be useful in treating basal cell carcinoma — the most common form of skin cancer, according to a study that was published online Feb. 3 in the Journal of Clinical Oncology.

The study tested itraconazole’s effectiveness in treating patients with multiple basal cell carcinoma tumors. Researchers at the Stanford University School of Medicine carried out a phase-2 clinical trial with 29 patients who had a total of 101 tumors. Within a month, the size and spread of tumors had decreased in most patients, they found.
Source: Stanford Medicine News Center

Itraconazole page


 

Plasma Cell Neoplasms (Including Multiple Myeloma)

 

Chinese Skullcap Scutellaria baicalensis
This study concluded that Chinese Skullcap inhibits the proliferation of myeloma cell lines by induction of apoptosis.

Pancreatic cancer

Additional Pancreatic Cancer Treatments

Vitamin C and Doxycycline
This study found that antibiotics, such as Doxycycline, could eradicate Cancer Stem Cells in multiple cancer types. These include: DCIS, breast (ER(+) and ER(-)), ovarian, prostate, lung, and pancreatic carcinomas, as well as melanoma and glioblastoma. The study authors propose the combined use of Doxycycline and Vitamin C as a new strategy for eradicating CSCs.

Pancreatic enzymes
Pancreatic enzymes help break down fats, proteins and carbohydrates. Pancreatic insufficiency is the inability of the pancreas to secrete the enzymes needed for digestion. Having an insufficient amount of pancreatic enzymes is very common among people with pancreatic cancer.
See Pancreatic Enzymes for Pancreatic Cancer

Gonzalez Protocol
A successful alternative therapy that is being studied as a treatment for pancreatic cancer. It includes a special diet, nutritional supplements, pancreatic enzymes, and coffee enemas. The Gonzalez Protocol is available online at The Nicholas Gonzalez Foundation website.

See Gonzalez Protocol

Ukrain
This study concluded: We could show that in unresectable advanced pancreatic cancer, NSC-631570 [ukrain] alone and in combination with gemcitabine nearly doubled the median survival times in patients suffering from advanced pancreatic cancer.

This study says its results suggest that Ukrain can exert some effects on pancreatic tumor progression.


Diabetes drug slows down growth of pancreatic cancer

Metformin — a commonly used generic medication for type 2 diabetes — decreases the inflammation and fibrosis characteristic of the most common form of pancreatic cancer, the researchers said.

Source: The Indian Express

Researchers are likely to have uncovered a novel mechanism behind the ability of the common diabetes drug metformin to inhibit the progression of pancreatic cancer.

Diabetic patients taking metformin have a reduced risk of developing pancreatic cancer. Among patients who develop the tumour, those taking the drug may have a reduced risk of death, the study revealed.

Metformin — a commonly used generic medication for type 2 diabetes — decreases the inflammation and fibrosis characteristic of the most common form of pancreatic cancer, the researchers said.

This beneficial effect may be most prevalent in overweight and obese patients, the findings indicated.

“We found that metformin alleviates desmoplasia — an accumulation of dense connective tissue and tumour-associated immune cells that is a hallmark of pancreatic cancer,” said lead author Dai Fukumura — associate professor of radiation oncology at Harvard Medical School in Massachusetts, US.

The study focused on pancreatic ductal adenocarcinoma — the most common form of pancreatic cancer — which also accounts for almost 40,000 cancer deaths in the US ever year. Half of those diagnosed with this form of pancreatic cancer are overweight or obese, and up to 80 per cent have type 2 diabetes or are insulin resistant, said the researchers.

The researchers first found that levels of hyaluronan — a component of the extracellular matrix — were 30 per cent lower in tumour samples from overweight or obese patients who were taking metformin to treat diabetes than in those who did not take the drug. In obese mouse models, the researchers found that metformin treatment reduced levels of tumour-associated macrophages by 60 per cent and reduced expression of genes involved in remodeling the extracellular matrix of tumour tissue.

“Understanding the mechanism behind metformin’s effects on pancreatic and other cancers may help us identify biomarkers — such as patient body weight and increased tumour fibrosis — that can identify the patients for whom metformin treatment would be most beneficial,” the authors noted in a study published in the journal PLOS One.


Neem Tree Extract Demonstrates Anticancer Activity Against Pancreatic Cancer

Source: OncologyNurseAdvisor
Kathy Boltz, PhD

A natural extract from the neem tree of India has potential to treat pancreatic cancer, according to a study published in Scientific Reports.1

Nimbolide, a compound found in neem leaves, was tested against pancreatic cancer in cell lines and mice. These tests, conducted by biomedical scientists at Texas Tech University Health Sciences Center El Paso (TTUHSC El Paso), found that nimbolide stopped the growth and metastasis of pancreatic cancer, yet did not harm normal, healthy cells.

“The promise nimbolide has shown is amazing, and the specificity of the treatment toward cancer cells over normal cells is very intriguing,” said Rajkumar Lakshmanaswamy, PhD, an associate professor in the TTUHSC El Paso Center of Emphasis in Cancer.

Currently, pancreatic cancer is fatal for 94% of patients who develop the disease within 5 years of diagnosis. No effective treatments are available, and so it has the highest mortality rate of all cancers.

The compound reduced the capacity of pancreatic cancer cells to migrate and invade by 70%, so the cancerous cells did not become aggressive and spread. Metastasis is the chief cause of mortality from the disease.

Furthermore, cancer cell death was induced by nimbolide treatments, as the size and number of pancreatic cancer cell colonies decreased by 80%.

“Nimbolide seems to attack pancreatic cancer from all angles,” Lakshmanaswamy said. The study found that nimbolide increases the generation of reactive oxygen species, which induces apoptotic cell death mediated by the mitochondria of the cells.

“Many people in India actually eat neem and it doesn’t have harmful side effects, which suggests that using nimbolide for pancreatic cancer will not cause adverse effects like chemotherapy and radiation typically do,” said Ramadevi Subramani, PhD, postdoctoral researcher and lead author of the study.

The researchers emphasized that healthy cells were unharmed by nimbolide in both the in vitro and in vivo experiments. Next, the research team plans to pursue both preclinical and clinical investigations.

REFERENCE

  1. Subramani R, Gonzalez E, Arumugam A, et al. Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition [published online ahead of print February 11, 2016]. Sci Rep. doi:10.1038/srep19819.

New Treatments May Extend Pancreatic Cancer Survival

Source: Health.com
June 4, 2018

Innovative ways of using chemotherapy can significantly extend the lives of patients with pancreatic cancer, one of the most deadly cancers known, two new clinical trials report.

A four-drug chemo “cocktail” extended surgical patients’ lives by nearly two years over the current standard single-drug chemo regimen for pancreatic cancer, a clinical trial out of France has shown.

“You take overall survival from just under three years to almost five years,” said Dr. Daniel Labow, a cancer surgeon at Mount Sinai Hospital in New York City. “That, for pancreas cancer, is a relative home run because survival in general is so poor.”

Meanwhile, a second preliminary study from the Netherlands found that combining chemotherapy and radiation therapy before pancreatic cancer surgery extended overall survival, particularly for those patients whose tumors were successfully removed.

Read full article at Health.com


Medicinal cannabis ‘may improve survival’ of pancreatic cancer patients

Source: Independent.ie
Sally Wardle
July 31 2018

A study on mice found Cannabidiol improved survival rates.

A cannabis drug may help to extend the lives of pancreatic cancer patients undergoing chemotherapy, new research suggests.

Scientists found mice with the disease survived almost three times longer if they were treated with cannabinoid Cannabidiol (CBD) alongside chemotherapy.

Lead researcher Professor Marco Falasca, from Queen Mary University of London, said it was “a remarkable result”.

The study, published in journal Oncogene, examined the impact of CBD on mice with pancreatic cancer receiving common chemotherapy drug Gemcitabine.

Mice treated with this combination of drugs had a median survival of 56 days, compared to 20 days for those left untreated, while mice receiving chemotherapy alone lived for a median 23.5 days.

Professor Falasca said: “Cannabidiol is already approved for use in clinics, which means we can quickly go on to test this in human clinical trials.

“If we can reproduce these effects in humans, cannabidiol could be in use in cancer clinics almost immediately, compared to having to wait for authorities to approve a new drug.

“The life expectancy for pancreatic cancer patients has barely changed in the last 40 years because there are very few, and mostly only palliative care, treatments available.

“Given the five-year survival rate for people with pancreatic cancer is less than seven per cent, the discovery of new treatments and therapeutic strategies is urgently needed.”

The researchers said the drug combination appears to block a protein called GPR55, slowing the growth of pancreatic cancer cells.

CBD is a medical-grade cannabis extract containing virtually no high-inducing psychoactive chemicals.

It is already known to improve the side effects of chemotherapy, including nausea and vomiting, and so may also improve the quality of life for patients, the researchers said.


Bitter melon

Bitter melon juice diluted to just 5% in water showed remarkable potency in severely damaging all four pancreatic cancer cell lines researchers tested. The bitter melon reduced the viability of two cancer cell lines by 90%, while it knocked off the other two lines by a staggering 98%. And it did so after just 72 hours of treatment!

Bitter melon page 


 

Ovarian cancer

 

High-grade Serous Ovarian Cancer (HGSOC)

The anti-inflammatory drug Indomethacin increases survival in serous ovarian cancer patients according to this study. It found:
Indomethacin decreased survival of primary HGSOC tumor cells and interestingly, cisplatin resistant ovarian tumor cells…exhibited significantly higher cell death upon Indomethacin treatment.

Glycyrrhetinic acid
This study concluded that Glycyrrhetinic acid causes cell death in ovarian cancer cells by inducing apoptosis.

Personalised vaccines for ovarian cancer extend survival rate

Source: Figo.org
A study into the potential benefits of personalised vaccines to treat ovarian cancer in stage III and IV patients has found they can improve survival rates.

Scientists at the Ludwig Institute for Cancer Research in Switzerland discovered that a new type of vaccine induces novel, potent and clinically effective immune responses in those with recurrent forms of the disease.

The personalised vaccine is created using processed cells from the patient’s own tumour and put straight into the immune cells.

Sufficient quantities can be manufactured easily and the therapy has been found to be well-tolerated without complications in the process of administering it.

Researchers observed that the immune response in those given the vaccines was vigorous and targeted known cancer antigens and neoantigens expressed by the patient’s cancer cells.

Lana Kandalaft, adjunct researcher at Ludwig Lausanne, said: “This is the first time ever that a personalised vaccine made from the contents of whole cancer cells has been shown to produce immune responses against neoantigens.

“We’ve also shown that these immune responses are not just any responses, but the type that kill tumour cells, and that they correlate with better progression-free survival and better overall survival of patients.”

Luekemia

 

Vitamin D
This study says Vitamin D and its analogs have inhibitory effects on cancer stem cell signaling in various types of human cancer cells and may be promising therapeutic/preventive agents against Cancer Stem Cells.

This study says vitamin D is a well known inducer of the terminal differentiation of human myeloid leukemia cells…
Sunlight spurs the body to make vitamin D.
Food sources:
Fish such as salmon, tuna, and mackerel. Small amounts of vitamin D are found in beef liver, cheese, and egg yolks.

Chinese Skullcap Scutellaria baicalensis
This study concluded that that Chinese Skullcap inhibits the proliferation of lymphocytic leukemia cell lines by induction of apoptosis.

Melbourne drug a blood cancer game changer

A breakthrough drug with its origins in Melbourne is driving a major shift in the treatment of a range of blood cancers, with two new clinical trials of chemotherapy-free combinations demonstrating dramatic benefits for patients with hard-to-treat diseases.

Venetoclax is a targeted drug in tablet form that was developed based on scientific discoveries made at the Walter and Eliza Hall Institute of Medical Research, and Melbourne researchers from the Peter MacCallum Cancer Centre (Peter Mac) and The Royal Melbourne Hospital (RMH) continue to lead many of the ongoing clinical trials.

Results of two new venetoclax trials – the MURANO Study involving patients with Chronic Lymphocytic Leukaemia (CLL) and AIM Study in Mantle-Cell Lymphoma (MCL) – were recently published in the New England Journal of Medicine.

Both trials involved patients whose blood cancer had relapsed or was resistant to conventional treatment, used venetoclax in combination with another targeted drug, and these treatment combinations resulted in high rates of patients with no detectable cancer.

“That venetoclax is able to produce such dramatic results in this hard-to-treat patient group is remarkable, and has led to much excitement among blood cancer clinicians globally and the research community particularly in Melbourne where this drug was pioneered,” says Professor John Seymour, Director of Haematology at Peter Mac and RMH.

“The data shows venetoclax should replace chemotherapy altogether in patients with advanced forms of CLL – a practice-changing result which will rapidly translate into the standard of care globally.”

Read full article

Please share this page